Supply Chain Intelligence

ProQR Therapeutics N.V. Supply Chain

PRQR supply chain intelligence for ProQR Therapeutics N.V.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

PRQR ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

3Suppliers
13Customers
1Debt Items
20Related Chains

Source-Backed Evidence Depth

ProQR Therapeutics N.V. (PRQR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

18Total relationships
2Distinct source URLs
4High confidence
0.710Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

ProQR Therapeutics N.V. Suppliers

TickerNameConfidenceEvidence
LLY Eli Lilly and Company 72% — ​ ( ) The effect of changes in foreign exchange rates ​ — ​ — ​ — Other changes ​ ​ ​ ​ ​ ​ Interest expense ​ ​ — ​ — Interest paid ​ — ​ — ​ — Effect of waived loan agreements ​ — ​ — ​ — Effect …
LLY Eli Lilly and Company 72% Reciprocal relationship from LLY graph: Reciprocal relationship from PRQR graph: — ​ ( ) The effect of changes in foreign exchange rates ​ — ​ — ​ — Other changes ​ ​ ​ ​ ​ ​ Interest expense ​ ​ — ​…
MIRM Mirum Pharmaceuticals, Inc. 72% Reciprocal relationship from MIRM graph: with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorit…

ProQR Therapeutics N.V. Customers

TickerNameConfidenceEvidence
LLY Eli Lilly and Company 85% — ​ ( ) The effect of changes in foreign exchange rates ​ — ​ — ​ — Other changes ​ ​ ​ ​ ​ ​ Interest expense ​ ​ — ​ — Interest paid ​ — ​ — ​ — Effect of waived loan agreements ​ — ​ — ​ — Effect …
LLY Eli Lilly and Company 85% Reciprocal relationship from LLY graph: Reciprocal relationship from PRQR graph: — ​ ( ) The effect of changes in foreign exchange rates ​ — ​ — ​ — Other changes ​ ​ ​ ​ ​ ​ Interest expense ​ ​ — ​…
IONS Ionis Pharmaceuticals, Inc. 72% Reciprocal relationship from IONS graph: Reciprocal relationship from PRQR graph: Reciprocal relationship from IONS graph: Reciprocal relationship from PRQR graph: Reciprocal relationship from IONS g…
IONS Ionis Pharmaceuticals, Inc. 72% upport of our third-party information technology providers, our ISM addresses areas such as: ● Assessment and treatment of cyber and information security risks ● Assessment and treatment of informati…
MIRM Mirum Pharmaceuticals, Inc. 72% Reciprocal relationship from MIRM graph: future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced dem…
CAPITAL-RESOURCES CAPITAL-RESOURCES 62% he operating losses incurred since inception, the Company has no income tax provisions as at December 31, 2025. Realization of deferred tax assets is dependent on future earnings, if any, the timing …
CRS Carpenter Technology Corporation 62% Reciprocal relationship from CRS graph: Reciprocal relationship from PRQR graph: he operating losses incurred since inception, the Company has no income tax provisions as at December 31, 2025. Realiz…
KAMAL-THERAPEUTICS-INC KAMAL-THERAPEUTICS-INC 62% for an amount of € 361,000 (2024: € 430,000 ). Buildings and leasehold improvements include a right-of-use asset relating to the lease of the Company’s Leiden office and laboratory space, with a carr…
NITTO-DENKO-AVECIA-INC NITTO-DENKO-AVECIA-INC 62% upport of our third-party information technology providers, our ISM addresses areas such as: ● Assessment and treatment of cyber and information security risks ● Assessment and treatment of informati…
PHOENICIS-THERAPEUTICS-INC PHOENICIS-THERAPEUTICS-INC 62% for an amount of € 361,000 (2024: € 430,000 ). Buildings and leasehold improvements include a right-of-use asset relating to the lease of the Company’s Leiden office and laboratory space, with a carr…
WING Wingstop Inc. 62% Reciprocal relationship from WING graph: Reciprocal relationship from PRQR graph: Reciprocal relationship from WING graph: Reciprocal relationship from PRQR graph: Reciprocal relationship from WING g…
WINGS-THERAPEUTICS-INC WINGS-THERAPEUTICS-INC 62% for an amount of € 361,000 (2024: € 430,000 ). Buildings and leasehold improvements include a right-of-use asset relating to the lease of the Company’s Leiden office and laboratory space, with a carr…
YARROW-BIOTECHNOLOGY-INC YARROW-BIOTECHNOLOGY-INC 62% group) is available for immediate sale in its present condition. Management must be committed to the sale which should be expected to qualify for recognition as a completed sale within one year from …

ProQR Therapeutics N.V. Debt Obligations

InstrumentDescriptionConfidenceEvidence
PRQR-DEBT Debt stack $18.3M 90% Market cache reports total debt of $18.3M.

ProQR Therapeutics N.V. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for ProQR Therapeutics N.V..

ProQR Therapeutics N.V. Ownership

HolderNameConfidenceEvidence
PRQR-OWNER-ADAGE-CAPITAL-PARTNERS-GP-L-L-C ADAGE CAPITAL PARTNERS GP, L.L.C. 90% 13F overlay lists ADAGE CAPITAL PARTNERS GP, L.L.C. as top holder; 70 tracked holders.

ProQR Therapeutics N.V. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
BYSI BeyondSpring Inc. 100.00 2
ACRS Aclaris Therapeutics, Inc. 100.00 2
BCYC Bicycle Therapeutics plc 100.00 2
ALEC Alector, Inc. 100.00 2
CRS Carpenter Technology Corporation 100.00 1 ['customer']
ACIU AC Immune SA 100.00 2
AKTS Aktis Oncology, Inc. 100.00 2
VEEV Veeva Systems Inc. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
CMMB Chemomab Therapeutics Ltd. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
FHTX Foghorn Therapeutics Inc. 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2
NVO Novo Nordisk A/S 100.00 2
ARWR Arrowhead Pharmaceuticals, Inc. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for ProQR Therapeutics N.V..

Unlock full PRQR data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
PRQR
Unlock PRQR Supply Chain Data
Verified relationships include:
LLYEli Lilly and CompanySupplier72%
LLYEli Lilly and CompanySupplier72%
LLYEli Lilly and CompanyCustomer85%
LLYEli Lilly and CompanyCustomer85%
+14 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →